Theravance Biopharma's market cap is currently $475.02M. The company's EPS TTM is $-1.011; its P/E ratio is ―; Theravance Biopharma is scheduled to report earnings on March 3, 2025, and the estimated EPS forecast is $-0.21. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Income Statement
Total Revenue	$ 57.42M	$ 51.35M	$ 55.31M	$ 71.86M	$ 73.41M
Gross Profit	$ 16.80M	$ 44.76M	$ 48.02M	$ -189.10M	$ -145.83M
Operating Income	$ -56.03M	$ -91.96M	$ -257.78M	$ -297.76M	$ -251.91M
EBITDA	$ -40.87M	$ -79.86M	$ -249.39M	$ -294.00M	$ -203.29M
Net Income	$ -55.19M	$ -92.82M	$ -199.43M	$ -278.02M	$ -236.46M
Balance Sheet
Cash & Short-Term Investments	$ 102.43M	$ 327.48M	$ 173.47M	$ 292.94M	$ 280.83M
Total Assets	$ 382.00M	$ 607.40M	$ 374.82M	$ 469.06M	$ 408.83M
Total Debt	$ 49.16M	$ 74.12M	$ 652.08M	$ 647.06M	$ 492.92M
Net Debt	$ 9.61M	$ -224.05M	$ 562.12M	$ 565.59M	$ 434.85M
Total Liabilities	$ 169.00M	$ 165.60M	$ 713.39M	$ 772.81M	$ 632.67M
Stockholders' Equity	$ 213.00M	$ 441.80M	$ -338.57M	$ -303.75M	$ -223.84M
Cash Flow
Free Cash Flow	$ -29.48M	$ -187.56M	$ -211.26M	$ -257.02M	$ -241.37M
Operating Cash Flow	$ -27.00M	$ -186.99M	$ -207.86M	$ -250.40M	$ -238.20M
Investing Cash Flow	$ -32.70M	$ 1.15B	$ 124.49M	$ 10.72M	$ -83.05M
Financing Cash Flow	$ -198.93M	$ -758.81M	$ 91.86M	$ 263.08M	$ 1.29M

Currency in USD

Theravance Biopharma Earnings and Revenue History

Income Statement >

Theravance Biopharma Debt to Assets

Balance Sheet >

Theravance Biopharma Cash Flow

Cash Flow >

Theravance Biopharma Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing